BYETTA Drug Patent Profile

When do Byetta patents expire, and what generic alternatives are available?

Byetta is a drug marketed by Astrazeneca Ab and is included in one NDA.

The generic ingredient in BYETTA is exenatide synthetic. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the exenatide synthetic profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Byetta

A generic version of BYETTA was approved as exenatide synthetic by AMNEAL on November 19^th, 2024.

Summary for BYETTA

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BYETTA

Paragraph IV (Patent) Challenges for BYETTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BYETTA	Injection	exenatide synthetic	250 mg/mL, 1.2 mL and 2.4 mL prefilled syringe	021773	1	2014-06-11

US Patents and Regulatory Information for BYETTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	BYETTA	exenatide synthetic	INJECTABLE;SUBCUTANEOUS	021773-001	Apr 28, 2005		DISCN	Yes	No
Astrazeneca Ab	BYETTA	exenatide synthetic	INJECTABLE;SUBCUTANEOUS	021773-002	Apr 28, 2005		DISCN	Yes	No

International Patents for BYETTA

See the table below for patents covering BYETTA around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1658856	Exendines destinés à la suppression du glucagon (Exendins for glucagon suppression)
Australia	2006225304
Spain	2343072
Luxembourg	91342
European Patent Office	1941900
Austria	381939
Germany	60044041

Supplementary Protection Certificates for BYETTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0996459	464	Finland
1140145	30/2007	Austria		PRODUCT NAME: EXENATIDE; REGISTRATION NO/DATE: EU/1/06/362/001-004 20061120
1140145	91343	Luxembourg		91343, EXPIRES: 20211120
0996459	0790031-9	Sweden		PRODUCT NAME: EXANATID; REG. NO/DATE: EU/1/06/362/001 20061120
1734971	2012C/017	Belgium		PRODUCT NAME: EXENATIDE; AUTHORISATION NUMBER AND DATE: EU/1/11/696/001 20110617
1734971	300526	Netherlands		PRODUCT NAME: EXENATIDE; REGISTRATION NO/DATE: EU/1/11/696/001-002 20110617
0996459	SZ 31/2007	Austria		PRODUCT NAME: EXENATIDE

BYETTA Market Analysis and Financial Projection

Last updated: February 3, 2026

What Is BYETTA and What Are Its Fundamentals?

BYETTA (exenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist used primarily to treat type 2 diabetes. Approved by the FDA in April 2005, it is marketed by Eli Lilly and Boehringer Ingelheim. The drug is administered via subcutaneous injection twice weekly for its extended-release formulation, with a daily injection available as well.

The drug operates by stimulating insulin secretion and inhibiting glucagon release, effectively lowering blood glucose levels. It also promotes weight loss, which has contributed to its market appeal.

Market Size and Growth Trends

The global type 2 diabetes market was valued at approximately $74 billion in 2022. The GLP-1 receptor agonist subset, including BYETTA, accounted for an estimated $4 billion in sales in the same year. Key drivers are increasing prevalence of diabetes, expansion into obesity treatment, and competitive positioning against insulin therapies.

Forecasts project the GLP-1 market to grow at a compound annual growth rate (CAGR) of 13-15% through 2027, driven by new formulation approvals and expanding indications. BYETTA captures a significant share of this segment due to early market entrance and established safety profile.

Competitive Landscape and Market Position

Competitors include other GLP-1 therapies such as Novo Nordisk’s Victoza (liraglutide), Ozempic (semaglutide), and newer drugs like Rybelsus (oral semaglutide). These drugs feature longer half-lives, once-weekly dosing, or oral formulations, which influence market dynamics.

• Victoza: sales reached $2.9 billion in 2022.
• Ozempic: sales exceeded $6 billion in 2022.
• Rybelsus: approximately $2 billion in revenue.

BYETTA’s sales have plateaued or declined slightly due to these competitive pressures. Its patent expiration in certain markets has also fostered generic or biosimilar entries, exerting further price pressure.

Patent and Regulatory Status

Initially, BYETTA had patent protections lasting until 2025. Patent challenges and bioequivalence approvals are ongoing, with generics expected around 2024-2025, which could significantly impact sales.

The drug’s regulatory landscape remains stable in major markets, with recent focus on expanding indications to include obesity management and combination therapies.

R&D and Pipeline Overview

Boehringer Ingelheim and Eli Lilly continue R&D to develop next-generation GLP-1 agonists with longer action profiles, oral formulations, and dual or triple mechanisms that combine GLP-1 activity with other targets.

Pipeline candidates include once-weekly formulations, fixed-dose combos with basal insulin, and potential indications in cardiovascular and neurodegenerative diseases.

Investment Considerations

Strengths

• Established market presence.
• Proven efficacy for diabetes and weight loss.
• Expanding indications and formulations.

Weaknesses

• Patent expiry approaching.
• Intensifying competition from newer drugs.
• Price pressure from biosimilars.

Opportunities

• Growing demand for GLP-1 therapies.
• Potential for expanded indications.
• Development of oral and long-acting formulations.

Threats

• Generic entry reducing revenues.
• Market shift towards once-weekly and oral options.
• Regulatory delays for pipeline candidates.

Financials and Valuation Metrics

While proprietary sales data is limited due to competitive disclosures, the broader GLP-1 segment’s CAGR suggests growth potential for existing and pipeline products. Investors should monitor sales trends, patent expiries, and pipeline advancements to evaluate BYETTA’s long-term value.

A valuation based on comparables (Victoza, Ozempic) indicates a potential decline in revenues post-generic entry, with prognosis tied to pipeline success and market expansion.

Key Takeaways

• BYETTA faces declining sales due to patent expiration and competition.
• The GLP-1 market is expanding rapidly, driven by obesity and diabetes trends.
• Pipeline innovations aim to address current limitations (weekly dosing, oral options).
• Competitive landscape favors drugs with longer half-lives and convenience.
• Early-stage R&D could influence long-term therapeutic relevance.

FAQs

1. When will BYETTA face generic competition?
Patent protections in key markets are expected to expiry around 2024-2025. Bioequivalence approvals and patent challenges may influence this timeline.

2. How does BYETTA compare to newer GLP-1 drugs?
BYETTA requires twice-weekly injections; newer drugs like Ozempic and Rybelsus offer weekly or oral dosing, making them more convenient and preferred.

3. What are growth opportunities for BYETTA?
Expanding indications into obesity and cardiovascular risk management, along with pipeline advancements, could bolster long-term prospects.

4. How does pipeline development impact investment in the class?
Next-generation formulations, especially oral options, could sustain or increase market size despite generic competition.

5. What risks could undermine BYETTA’s value?
Patent expiration, price competition, and rapid adoption of oral or weekly alternatives pose significant threats.

---

References

1. “Diabetes Market Size & Share.” Grand View Research, 2022.
2. “Victoza (liraglutide) Sales Data.” Novo Nordisk, 2022.
3. “Ozempic (semaglutide) Sales Data.” Novo Nordisk, 2022.
4. “Rybelsus (oral semaglutide) Sales Data.” Novo Nordisk, 2022.
5. “Boehringer Ingelheim and Eli Lilly Pipeline Updates.” ClinicalTrials.gov, 2023.